MedTrace Logo

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

NCT02442414 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2022-03-04

No results posted yet for this study

Summary

The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.

Conditions

Interventions

DRUG

KBP-5209

Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.

Sponsors & Collaborators

  • Covance

    collaborator INDUSTRY

  • XuanZhu Pharma Co., Ltd.

    collaborator UNKNOWN

  • Sihuan Pharmaceutical Holdings Group Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-07
Primary Completion
2019-11-26
Completion
2019-11-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02442414 on ClinicalTrials.gov